Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does reducing a patient's CRP levels with statin therapy reduce their risk of recurrent cardiovascular events?

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Zee RY and Ridker PM (2002) Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 162: 217–219

    Article  CAS  Google Scholar 

  2. Kluft C and de Maat MP (2003) Genetics of C-reactive protein: new possibilities and complications. Arterioscler Thromb Vasc Biol 23: 1956–1959

    Article  CAS  Google Scholar 

  3. Freedman LS et al. (1992) Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11: 167–178

    Article  CAS  Google Scholar 

  4. Ridker PM and JUPITER Study Group (2003) Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108: 2292–2297

    Article  Google Scholar 

  5. van de Ree MA et al. (2003) Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 166: 129–135

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jenny Buckland, Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Cornelis Kluft.

Ethics declarations

Competing interests

C Kluft has received research grants from Pfizer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kluft, C. Does reducing a patient's CRP levels with statin therapy reduce their risk of recurrent cardiovascular events?. Nat Rev Cardiol 2, 244–245 (2005). https://doi.org/10.1038/ncpcardio0196

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0196

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing